← All Inflarx NV filings

Inflarx NV 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
IFRX
Inflarx NV
20-F: InflaRx Shifts Focus to Izicopan, Cuts GOHIBIC Commercial Efforts
InflaRx N.V. reported a net loss of €45.6 million for 2025, shifting its strategic focus to the oral C5aR inhibitor izicopan after discontinuing active commercialization of GOHIBIC (vilobelimab) in the U.S. due to lack of commercial success.
NASDAQ
IFRX
Inflarx NV
20-F: InflaRx N.V. Files 20-F Annual Report, Providing Comprehensive Update on Financials and Operations
InflaRx N.V. released its annual report on Form 20-F, detailing the company's financial results for the year ended December 31, 2024, and providing an overview of its operations, product development, and corporate governance.
NASDAQ
IFRX
Inflarx NV
20-F: InflaRx N.V. Reports Financial Results for Fiscal Year 2023 and Provides Business Update
InflaRx N.V. details its financial performance for 2023, highlighting progress in commercializing GOHIBIC and advancing its pipeline.